Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,

Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343

Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050

September 03, 2024

National Stock Exchange of India Limited

Scrip Symbol: SUNPHARMA

SUN PHARMA

BSE Limited Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Regulatory Order

This is to inform that a subsidiary (Sun Pharma Distributors Limited) of the Company has received an order passed by statutory authority. Relevant details, as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are provided in Annexure A.

The Company shall take appropriate action in the matter.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)

Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,

Western Express Highway, Goregaon (E), Mumbai – 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343

Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Information
a)	Name of the authority	Joint Commissioner of State Tax, Kadamkuan Circle, Patna
b)	Nature and details of the action(s) taken, initiated, or order(s) passed	Order passed u/s 73(9) of the SGST/CGST Act, 2017, imposing interest of Rs. 7,74,060/- and penalty of Rs. 1,39,238/-
c)	Date of receipt of direction or order, including any ad-interim or interim orders or any other communication from the authority	September 03, 2024
d)	Details of the violation(s)/ contravention(s) Committed or alleged to be committed	Disallowance of ITC
e)	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on the Company's financial, operation or other activities.